Prot #IS00011961: The Mechanism Of ST100021 On Neurotransmitter Efflux Related To Psychosis

Project: Research project

Project Details


The ability of atypical antipsychotic drugs (APDs) to improve some domains of cognitive impairment of schizophrenia may be due, in part, to increased release of dopamine (DA) and acetylcholine (ACh) in cortical and temporal lobe regions. Typical APDs cause little or no DA or ACh efflux in rodent mPFC and hippocampus and have lesser effect on cognitive impairment in schizophrenia. Rodent cortical or hippocampal DA, ACh, and glutamate (Glu) efflux in microdialysis samples is increased during performance of attention and working memory tasks during. In the present study, we will study the effect of ST100021 and compare its effect and selective serotonin receptor modulators as well as the typical and atypical APD from archived data of Meltzer’s lab, on the efflux of cortical DA, ACh, Glu, GABA, serine, glycine, 5-HT, and the metabolites, dihydroxyphenylacetic acid (DOPAC), homovanillac acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA).
Effective start/end date5/19/205/18/21


  • Dainippon Sumitomo Pharma Co., Ltd. (Prot #IS00011961)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.